ABSTRACT
Introduction and background: Adenosine deaminase (ADA) is an enzyme produced from body cells after infections due to activations of the immune response toward the microbes. The enzyme was previously used for the diagnosis of tuberculosis, lymphomas, sarcoidosis, lupus, and severe combined immunodeficiency (SCID). COVID-19 is a viral disease caused by Coronaviruses and infected the respiratory tract of patients mainly. The aim of this study is to measure and correlate the level of ADA with COVID-19 during the infection, patient and methods: Two methods;conventional enzymatic (Guisti and Galanti method) and ELISA methods were used to measure the level of ADA in 48 individuals, 12 were suffering from severe COVID-19, 12 has a moderate infection and 24 individuals were used as the control they are negative PCR- COVID-19 infections. Results: Both methods show that the level of ADA in patients suffering from COVID-19 infection is significantly higher in patients with severe infections compared with those in control and moderate infections' P <0.001, conclusion: This study concluded that the use of ADA levels in the serum of COVID-19 patients will be useful during the period of the disease. © 2022, HIV Nursing. All rights reserved.